PHERGAIN-2

OFFICIAL TITLE: CHEMOTHERAPY-FREE PCR-GUIDED STRATEGY WITH SUBCUTANEOUS TRASTUZUMAB-PERTUZUMAB AND T-DM1 IN HER2-POSITIVE EARLY BREAST CANCER (PHERGAIN-2)

PLANNED SITES

HER2+ EBC

II

393

70

Spain, Italy, Germany, Hungary, Bulgaria, Poland

Recruitment

SCIENTIFIC MEETINGS

home_fondo_you_barra.jpg

SABCS 2021: - DOWNLOAD THE POSTER

home_fondo_you_barra.jpg

SPAIN

Hospital General Universitario de Valencia

SPAIN

Hospital Universitari Dexeus

SPAIN

Hospital Arnau de Vilanova de Valencia

SPAIN

Hospital Universitario Virgen del Rocío

SPAIN

Hospital Universitari Sant Joan de Reus

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Hospital Universitario de Basurto

SPAIN

Hospital General Universitario de Alicante

SPAIN

Hospital Provincial de Castellón

SPAIN

Instituto Valenciano de Oncología

SPAIN

Complejo Hospitalario de Jaén

SPAIN

Complejo Hospitalario Universitario A Coruña (CHUAC),

SPAIN

Hospital Universitario Reina Sofía

SPAIN

Hospital Clínico Universitario de Valencia

SPAIN

Institut Català d' Oncologia L'Hospitalet (ICO)

SPAIN

Hospital Clínico San Carlos

SPAIN

Hospital Universitario de León

SPAIN

Hospital Universitari Vall D'Hebrón

SPAIN

Hospital Quiron San Camilo- Ruber Juan Bravo

SPAIN

Hospital Universitario Clínico San Cecilio de Granada

SPAIN

Institut Català d'Oncologia Badalona (ICO)

SPAIN

Centro Oncológico de Galicia

SPAIN

Hospital Universitario de Torrejón

SPAIN

Hospital Arnau de Vilanova de Lleida

CLINICAL TRIAL DETAILS

THIS CLINICAL TRIAL EVALUATES THE EFFICACY OF A CHEMOTHERAPY-FREE PATHOLOGICAL COMPLETE RESPONSE (PCR)-GUIDED STRATEGY WITH TRASTUZUMAB AND PERTUZUMAB (GIVEN AS A SUBCUTANEOUS FIXED-DOSE COMBINATION) AND T-DM1, FOR PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE EARLY BREAST CANCER, BY ASSESSING THE 3-YEAR RECURRENCE FREE INTERVAL (3Y-RFI).

IN ADDITION, THE TRIAL WILL ASSESS THE GLOBAL HEALTH STATUS DECLINE RATE AT 1 YEAR FROM START OF NEOADJUVANT TREATMENT IN THIS TARGET POPULATION.




PHERGAIN-2 AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

N

COUNTRY

STATUS

PHERGAIN-2 ACTIVATED SITES